Athira Pharma, INC 8-K filings

LeonaBio announced its second quarter 2026 financial results, highlighting progress in its Phase 3 ELAINE-3 trial for lasofoxifene and providing a business update.

LeonaBio reported first quarter 2026 financial results, highlighting progress in its Phase 3 lasofoxifene trial for metastatic breast cancer and upcoming Phase 2 study for ATH-1105 in ALS.

LeonaBio, Inc. (formerly Athira Pharma) has acquired exclusive global rights to lasofoxifene, a Phase 3 metastatic breast cancer candidate, backed by up to $236 million in financing.

LeonaBio, Inc. reported full year 2025 financial results, highlighted a strategic shift with the acquisition of a Phase 3 breast cancer drug license, and secured $90 million in private placement financing.

LeonaBio, Inc. stockholders approved a new 2026 Equity Incentive Plan and a significant increase in authorized common stock, alongside warrant exercises.

Athira Pharma rebrands as LeonaBio, Inc., changes ticker to LONA, and updates CFO severance terms, signaling a strategic shift towards late-stage oncology and neurodegenerative assets.

Athira Pharma has announced a $90 million private placement and an exclusive global license for late-stage breast cancer drug lasofoxifene, diversifying its pipeline and extending its cash runway into 2028.

Athira Pharma announced a $90 million private placement and an exclusive global license for lasofoxifene, a Phase 3 metastatic breast cancer candidate, extending its cash runway into 2028.

Athira Pharma reported its third-quarter 2025 financial results, highlighting progress in its ATH-1105 clinical program and ongoing exploration of strategic alternatives to maximize stockholder value.

Athira Pharma, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously reported listing matter.

Athira Pharma will effect a 10-for-1 reverse stock split to meet Nasdaq listing requirements and enhance marketability, effective September 17, 2025.

Athira Pharma announced its second quarter 2025 financial results, highlighting positive Phase 1 data for ATH-1105 in ALS and ongoing strategic alternatives exploration.

Athira Pharma, Inc. announced that its stockholders approved a reverse stock split and elected three Class II directors at its 2025 Annual Meeting, alongside ratifying Ernst & Young LLP as its independent auditor.

Athira Pharma announces completion of Phase 1 clinical study of ATH-1105 for ALS and reports Q1 2025 financial results, highlighting progress in pipeline development and strategic alternatives exploration.

Athira Pharma receives Nasdaq approval to transfer its listing to the Nasdaq Capital Market and gains an extension to meet minimum bid price requirements.

Athira Pharma announces its full year 2024 financial results, highlighting progress in its pipeline, particularly with ATH-1105 for ALS treatment, and ongoing exploration of strategic alternatives.

Athira Pharma announced its third quarter 2024 financial results, highlighted by the continued development of its ALS drug candidate, ATH-1105, and the exploration of strategic alternatives.

Athira Pharma received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, while also planning to file a new $300 million shelf registration.

Athira Pharma has announced the departure of two key executives as part of a workforce reduction, while also implementing retention incentives for remaining leadership.

Athira Pharma is reducing its workforce by 70% and focusing on the development of ATH-1105 for neurodegenerative diseases, including ALS.

Athira Pharma's Phase 2/3 LIFT-AD trial for fosgonimeton in Alzheimer's disease did not meet its primary endpoint, but showed positive trends in certain patient subgroups and biomarkers.

Athira Pharma reported its second quarter 2024 financial results, highlighted by the upcoming topline data release from its Phase 2/3 LIFT-AD clinical trial in September 2024 and progress in its other clinical programs.

Athira Pharma successfully held its 2024 Annual Meeting of Stockholders, electing three Class I directors and approving an amendment to the company's charter to limit officer liability.

Athira Pharma has received preliminary court approval for a settlement in a stockholder derivative lawsuit, which includes corporate governance reforms and payment of legal fees.

Athira Pharma announced its first quarter 2024 financial results and provided updates on its clinical pipeline, including the anticipated topline data from the LIFT-AD trial in the second half of 2024.

Athira Pharma reports full year 2023 financial results, completes enrollment in a Phase 2/3 Alzheimer's trial, and is on track to initiate a first-in-human study for ALS treatment.